1,200 articles
Marlies Meisel
Marlies Meisel is an Austrian-trained cellular immunologist and microbiome researcher at the University of Pittsburgh, known for showing that bacteria inside tumors can change how cancer immunotherapy works.
Marsha A. Moses
Marsha A. Moses is an American biochemist and cancer researcher who directs the Vascular Biology Program at Boston Children's Hospital and is a Harvard Medical School professor.
Marshall R. Posner
Marshall R. Posner is an American medical oncologist known for leading the phase 3 TAX 324 trial of TPF chemotherapy for head and neck cancer and rituximab therapy for pemphigus vulgaris.
Martha S. Linet
Martha S. Linet is an American physician epidemiologist who led the National Cancer Institute's Radiation Epidemiology Branch from 2002 to 2014, known for research on leukemia and radiation health effects.
Martin A. Cheever
Martin A. Cheever was an American oncologist and cancer immunotherapy researcher at Fred Hutchinson Cancer Research Center in Seattle who founded the Cancer Immunotherapy Trials Network.
Martin H.N. Tattersall
Martin H.N. Tattersall (1941–2020) was a British-born Australian medical oncologist, the first professor of cancer medicine in the southern hemisphere, at the University of Sydney from 1977.
Martin J. van den Bent
Martin J. van den Bent, also written Martin van den Bent, is a Dutch neurologist and neuro-oncologist who led the Neuro-Oncology Unit at Erasmus MC, Rotterdam, and led the CATNON glioma trial.
Martin Reck
Martin Reck (M. Reck) is a German medical oncologist who heads thoracic oncology and clinical trials at LungenClinic Grosshansdorf, Germany, and is known for lung cancer immunotherapy research.
Martin Schlumberger
Martin Schlumberger is a French thyroid-cancer oncologist and nuclear medicine specialist who headed Gustave Roussy's nuclear medicine department from 1980 to 2019 and led the SELECT lenvatinib trial.
Martin Schrappe
Martin Schrappe is a German pediatric oncologist known for risk-adapted trials in childhood acute lymphoblastic leukemia, chairing the International BFM Study Group from 2001 to 2016.
Martine F. Roussel
Martine F. Roussel is a French-born molecular oncologist at St. Jude Children's Research Hospital in Memphis, known for identifying the FMS oncogene as a growth-factor receptor and discovering D-type cyclins.
Martine Piccart
Martine Piccart is a Belgian medical oncologist, Scientific Director at the Institut Jules Bordet in Brussels, who led the HERA and MINDACT trials and co-founded the Breast International Group.
Masaki Mori
Masaki Mori (森 正樹) is a Japanese digestive surgeon and physician-scientist, chairman professor of gastroenterological surgery at Osaka University from 2008, known for gastrointestinal cancer research.
Masanori Hatakeyama
Masanori Hatakeyama (畠山 昌則, born 1956) is a Japanese molecular oncologist known for establishing the Helicobacter pylori CagA protein as the first bacterium-derived oncoprotein in gastric cancer.
Massimiliano Mazzone
Massimiliano Mazzone is an Italian tumor immunologist and full professor at KU Leuven who heads the Laboratory of Tumor Inflammation and Angiogenesis at the VIB-KU Leuven Center for Cancer Biology in Belgium.
Massimo Cristofanilli
Massimo Cristofanilli is an Italian-born American medical oncologist specializing in breast cancer and liquid biopsy, known for his landmark 2004 New England Journal of Medicine study.
Massimo Loda
Massimo Loda is an Italian-born American molecular pathologist who chairs pathology at Weill Cornell Medicine and was elected to the National Academy of Medicine in 2024 for showing prostate tumors depend on lipids.
Mathias Heikenwälder
Mathias Heikenwälder, born 1976, is a German molecular biologist and immunologist who heads the Division of Chronic Inflammation and Cancer at the German Cancer Research Center in Heidelberg.
Mathieu Lupien
Mathieu Lupien is a French-Canadian cancer researcher and Senior Scientist at the Princess Margaret Cancer Centre who studies how the epigenome controls gene activity in cancer.
Matthew D. Galsky
Matthew D. Galsky is an American medical oncologist at Mount Sinai specializing in bladder and other genitourinary cancers, leading phase 3 immunotherapy trials in urothelial carcinoma.
Matthew D. Hellmann
Matthew D. Hellmann is a medical oncologist and drug developer, formerly of Memorial Sloan Kettering, known as lead author of the CheckMate 227 lung cancer immunotherapy trial reports.
Matthew G. Vander Heiden
Matthew G. Vander Heiden is an American physician-scientist at MIT who studies cancer metabolism, directs the Koch Institute, and was elected to the National Academy of Medicine in 2024.
Matthew J. Ellis
Matthew J. Ellis is a breast cancer oncologist and cancer genomics researcher who directed the Lester and Sue Smith Breast Center at Baylor and joined AstraZeneca in 2022.
Matthew L. Freedman
Matthew L. Freedman is a physician-scientist in cancer genomics, Professor of Medicine at Harvard Medical School and holder of the David Goldstein Chair at Dana-Farber Cancer Institute.
Matthew R. Smith
Matthew R. Smith, also published as Matthew Raymond Smith, is an American medical oncologist specializing in prostate cancer who directs the Genitourinary Malignancies Program at Mass General Cancer Center.
Matthias Ernst
Matthias Ernst is an Australian cancer biologist who studies inflammation-driven gastrointestinal cancers and became the inaugural Scientific Director of the Olivia Newton-John Cancer Research Institute in 2015.
Matthias Preusser
Matthias Preusser is an Austrian medical oncologist and neuro-oncologist, head of oncology at the Medical University of Vienna since 2018 and a past president of EANO.
Maud Slye
Maud Slye was an American pathologist at the University of Chicago whose breeding program of roughly 140,000 mice helped establish heredity as central to cancer research.
Maura L. Gillison
Maura L. Gillison (1965–2026) was a Canadian-born medical oncologist and molecular epidemiologist who established HPV as the cause of a distinct, better-prognosis subset of oropharyngeal cancers.
Maurizio Scaltriti
Maurizio Scaltriti is an Italian cancer biologist who has led translational medicine in early oncology at AstraZeneca since 2020, after research at Memorial Sloan Kettering.